Medicare Now Reimburses Cannabis Products Despite Widespread Contamination Risks
Washington, Monday, 1 June 2026.
As of June 2026, Medicare reimburses state-licensed cannabis despite data revealing 70% of products contain dangerous toxins. Federal courts dismissed safety lawsuits, creating unprecedented health and regulatory risks.
A Fast-Tracked Federal Pipeline Riddled with Risks
Under a sweeping shift in federal healthcare policy finalized on May 31, 2026, the Drug Enforcement Administration (DEA) established an expedited Schedule III registration pathway for state-licensed cannabis operators [1]. This follows the April 1, 2026, launch of the Centers for Medicare & Medicaid Services (CMS) Substance Access Pilot Program, which allows participating healthcare organizations to distribute hemp-derived products to older Americans [2]. Yet, this rapid integration bypasses traditional pharmaceutical safety protocols. The U.S. Food and Drug Administration (FDA) suspended enforcement of 21 CFR Part 211 manufacturing controls for hemp-derived CBD distributed to Medicare seniors on April 1, 2026 [1].
The Political Push and Economic Relief
The momentum behind these regulatory changes is largely driven by a bipartisan political desire to reshape federal cannabis policy and unlock economic growth. In December 2025, Republican President Donald Trump issued an executive order instructing Attorney General Pam Bindi to accelerate the rescheduling of marijuana to Schedule III [4]. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. noted that while the previous Biden administration initiated the proposal, it had become “mired down in the chaos, and inertia, and disorganization” [4]. The reclassification eliminates the burdensome Section 280E tax provision, which analytics firm Headset estimates will save a median U.S. dispensary between $268,000 and $805,000 annually [4]. Legislative efforts like the HEMP Act, introduced in January 2026 by Representatives Morgan Griffith (R-VA) and Marc Veasey (D-TX), further reflect congressional intent to stabilize the hemp marketplace by pushing for a formal FDA framework [4].
Courts Close the Door on Safety Challenges
Despite glaring safety concerns, legal avenues to halt the Medicare pilot program have been firmly shut. On May 31, 2026, U.S. District Judge Trevor N. McFadden of the District of Columbia dismissed the lawsuit Smart Approaches to Marijuana, et al. v. Robert F. Kennedy, Jr., et al. [3]. The lawsuit, filed against HHS Secretary Kennedy and CMS Administrator Mehmet Oz, argued that the CMS Billing/Benefit Expansion Initiative (BEI) unlawfully permitted the distribution of non-FDA-approved cannabinoids [3]. Judge McFadden ruled that the plaintiffs—which included 11 anti-drug organizations, a physician, and a Medicare beneficiary—lacked Article III standing, characterizing their anticipated injuries as “too abstract or too remote to open the courtroom doors” [3].
What This Means for Healthcare and Investors
For healthcare providers participating in value-based care models, such as the ACO REACH Model, the CMS Substance Access Beneficiary Engagement Incentive allows them to furnish up to $500 annually in hemp products to qualifying seniors [2][3]. Crucially, these products are funded entirely through the internal budgets of the participating clinics, requiring no separate insurance billing or pharmacy co-pays from the patients [2]. Medicare plans to evaluate clinical evidence gathered throughout 2026 to determine how cannabinoids affect seniors’ physical activity and mental well-being before deciding on permanent integration into the federal healthcare model [2].